Clinical Report: Evaluating the Diagnostic Precision of Plasma Biomarkers for mTBI
Overview
Revise to specify the findings on diagnostic accuracy and clarify the context of ambiguous clinical signs.
Background
Mild traumatic brain injury (mTBI) poses significant challenges in diagnosis, especially among older adults who experience worse outcomes compared to younger patients. The subjective nature of clinical signs and symptoms complicates the diagnostic process, necessitating objective measures. Blood-based biomarkers present a potential solution to improve diagnostic certainty in this vulnerable population.
Data Highlights
This study involved a comparison of biomarker performance between diagnosed mTBI cases and healthy controls, establishing age- and sex-adjusted diagnostic thresholds.
Key Findings
GFAP and UCH-L1 are already approved to rule out head CT scans in adults with suspected mTBI.
Older adults show significantly higher and more variable baseline plasma concentrations of key biomarkers like GFAP and NfL.
The study aims to assess the utility of biomarkers within 72 hours post-injury in older adults.
Multiple biomarker combinations may improve diagnostic accuracy in clinically ambiguous cases.
Current U.S. guidelines recommend biomarkers as adjuncts to clinical assessment rather than standalone diagnostic tools.
Clinical Implications
Highlight the importance of understanding biomarker variability in clinical decision-making.
Conclusion
Reiterate the significance of findings in relation to current diagnostic practices.
by Gershon Spitz, Jake Mitchell, Beatrice Duarte Martins, Abigail Astridge, Charlotte Copas, William T. O’Brien, Georgia F. Symons, Meng Law, Terence J. O’Brien, Matthew P. Pase, Jennie L. Ponsford, Biswadev Mitra, Stuart J. McDonald, Sandy R. Shultz
